



US008071073B2

(12) United States Patent
Dang et al.**(10) Patent No.: US 8,071,073 B2**
(45) Date of Patent: Dec. 6, 2011**(54) COMPOSITIONS COMPRISING
AZELASTINE AND METHODS OF USE
THEREOF****(75) Inventors:** **Phuong Grace Dang**, Corona, CA (US);
Brian D. Lawrence, Somerset, NJ (US);
Gul Balwani, West Windsor, NJ (US);
Alexander D. D'Addio, Piscataway, NJ
(US)**(73) Assignee:** **MEDA Pharmaceuticals Inc.**,
Somerset, NJ (US)**(*) Notice:** Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 925 days.**(21) Appl. No.: 11/284,109****(22) Filed: Nov. 22, 2005****(65) Prior Publication Data**

US 2006/0110331 A1 May 25, 2006

Related U.S. Application Data**(60)** Provisional application No. 60/630,274, filed on Nov.
24, 2004.**(51) Int. Cl.****A61L 9/04** (2006.01)**A61K 31/55** (2006.01)**A61K 9/20** (2006.01)**(52) U.S. Cl. 424/45; 424/464; 424/489; 514/2.3;**
514/171**(58) Field of Classification Search 514/217.05;**
424/45, 464

See application file for complete search history.

(56) References Cited**U.S. PATENT DOCUMENTS**158,564 A 1/1875 Barnes
2,119,643 A 6/1938 Mendl
2,136,940 A 11/1938 Ehbrecht
2,457,024 A 12/1948 Arp
2,822,314 A 2/1958 Ferlauto et al.
2,925,417 A 2/1960 Elslager et al.
2,995,308 A 8/1961 Ashkenaz
3,017,411 A 1/1962 Engelbrecht et al.
3,144,485 A 8/1964 Benn et al.
3,173,876 A 3/1965 Zobrist
3,267,586 A 8/1966 Molstedt et al.
3,541,005 A 11/1970 Strathmann et al.
3,541,006 A 11/1970 Bixler et al.
3,546,142 A 12/1970 Michaels et al.
3,753,988 A 8/1973 Rodway et al.
3,813,384 A 5/1974 Vogelsang et al.
3,845,052 A 10/1974 Stachel et al.
3,854,770 A 12/1974 Grise et al.
3,878,217 A 4/1975 Carr et al.
4,061,768 A 12/1977 Gorvin
4,077,407 A 3/1978 Theeuwes et al.
4,091,108 A 5/1978 Batchelor et al.
4,094,968 A 6/1978 Hodson et al.
4,226,848 A 10/1980 Nagai et al.
4,235,236 A 11/1980 Theeuwes
4,254,129 A 3/1981 Carr et al.4,313,931 A 2/1982 Walther et al.
4,430,343 A 2/1984 Iemura et al.
4,435,440 A 3/1984 Hough et al.
4,449,983 A 5/1984 Cortese et al.
4,455,143 A 6/1984 Theeuwes et al.
4,495,170 A 1/1985 Beyts et al.
4,501,893 A 2/1985 Findlay et al.
4,570,630 A 2/1986 Elliott et al.
4,602,099 A 7/1986 Parker
4,621,094 A 11/1986 Findlay et al.
4,628,055 A 12/1986 Sherlock
4,704,285 A 11/1987 Alderman
4,704,387 A 11/1987 Engel et al.
4,728,509 A 3/1988 Shimizu et al.
4,738,984 A 4/1988 Parker
4,749,700 A 6/1988 Wenig
4,751,294 A 6/1988 Jackson
4,769,369 A 9/1988 Thomas et al.
4,795,754 A 1/1989 Sawaki et al.
4,810,716 A 3/1989 Connor et al.
4,811,731 A 3/1989 Newell et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU 37674/72 7/1973

(Continued)

OTHER PUBLICATIONSWilson and Gisvold's Textbook of Organic Medicinal and Pharma-
ceutical Chemistry: Edition: 11, Published by Lippincott Williams &
Wilkins, 2004, p. 717.* Wilson and Gisvold's Textbook of Organic
Medicinal and Pharmaceutical Chemistry: Edition 11, published by
Lippincott Williams and Wilkins, 2004, p. 717.*
Drug Facts and Comparisons, 1994 edition, Wolters Kluwer Com-
pany, p. 986 and p. 975.*
Pharmaceutical Dosage Forms and Drug Delivery Systems, Ansel et
al., 7th edition, Lippincott Williams & Wilkins, 1999, pp. 93-98.*
Gray, Henry. Anatomy of the Human Body. Philadelphia: Lea &
Febiger, 1918; Bartleby.com, 2000. www.bartleby.com/107/.
[Printed Jan. 29, 2010].*

(Continued)

Primary Examiner — Brandon Fetterolf*Assistant Examiner* — Dennis Heyer**(74) Attorney, Agent, or Firm** — Sterne, Kessler, Goldstein
& Fox P.L.L.C.**(57) ABSTRACT**The present invention provides pharmaceutical compositions
comprising azelastine, or a pharmaceutically acceptable salt
or ester thereof including azelastine hydrochloride, and
optionally one or more additional active agents. Preferred
such compositions further comprise one or more pharmaceu-
tically acceptable carriers or excipients that reduce the
amount of post-nasal drip, and/or that minimize or mask the
unpleasant bitter taste associated with post-nasal drip, of the
compositions into the oral cavity, upon intranasal or ocular
administration of the compositions. Especially effective
excipients used in the compositions of the present invention
are hypromellose as a viscosity modifier and sucralose as a
taste-masking agent. The invention also provides methods of
treating or preventing certain disorders, or symptomatic relief
therefrom, by administering the compositions of the inven-
tion to a patient, e.g., for the symptomatic relief of allergic
rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivi-
tis, as well as other disorders. The compositions and methods
of the present invention provide significant value in terms of
patient acceptability, convenience, and compliance.**28 Claims, No Drawings**